Close Menu
June 18, 2019
Sponsored by
ArcherDX

Clinical Genomics of NTRK Fusion Detection in Cancer

GenomeWebinar

Associate Director, Laboratory for Molecular Pediatric Pathology; Staff Pathologist, Boston Children's Hospital; Instructor of Pathology, Harvard Medical School

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. This webinar will provide an overview and background about the increased role of these fusions, and latest trends in diagnosis, prognosis, and treatment, as well as a research case study on detection.

Join Dr. Alanna Church of the Laboratory for Molecular Pediatric Pathology and Staff Pathologist at Boston Children's Hospital to learn more about the increasing role of NTRK fusions:

  •  Overview and background of fusion mutations, specifically NTRK 1, 2, and 3
  •  Frequency overview and specificity needed for detection
  •  Overview of research case of utilizing NGS technology in detection.
Sponsored by

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Jun
04
Sponsored by
NanoCellect

This webinar will discuss a study that used CRISPR/Cas9 to engineer mice harboring risk variants associated with glaucoma in order to assess their functional relevance. 

Jun
06
Sponsored by
NRGene & Illumina

This webinar will discuss the impact of affordable de novo genome assemblies on crop research.

Jun
11
Sponsored by
Roche

This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.

Jun
13
Sponsored by
Roche

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.